Aim Preoperative anaemia is associated with adverse outcomes in colorectal cancer (CRC). To clarify the reason for this we aimed to comprehensively assess the association of preoperative anaemia with tumour characteristics, host systemic inflammation and nutrition status, and perioperative blood transfusion.
Introduction
Anaemia can occur due to bleeding, iron metabolic disorders, nutritional deficiencies and chronic systemic inflammation [1, 2] . Anaemia is categorized by the mean corpuscular volume (MCV) as microcytic (< 80 fl), normocytic (80-100 fl) or macrocytic (> 100 fl), which facilitates the diagnosis of certain diseases. Cancer and anaemia are closely linked, as anaemia is caused by tumour bleeding, poor nutrition and chronic inflammation due to the cancer process. Furthermore, lower haemoglobin (Hb) levels cause a reduction in blood oxygenation and this might lead to tumour hypoxia, which in turn activates cancer progression through upregulation of hypoxia-inducible factor-1 alpha (HIF-1a) [3] . While some studies have demonstrated that pretreatment anaemia is an adverse prognosticator in various cancers [4] [5] [6] , others have shown that this depends on the anaemic subtype, cancer type and cancer stage [7, 8] .
Colorectal cancer (CRC) is frequently detected by faecal occult blood testing and strongly correlates with anaemia. Studies have assessed the prognostic or predictive value of anaemia in CRC, and have reported an association between anaemia and adverse outcomes after resection [9, 10] , chemotherapy [11] or radiotherapy [12] . Interestingly, anaemia has been correlated with the systemic inflammatory response [9] and serum total lymphocyte count [13] , supporting the pathogenic and immunogenic influence of anaemia on cancer status. However, there are few studies that have comprehensively assessed the clinical characteristics and the prognostic value of anaemic subtypes in CRC. Given the importance of preoperative anaemia for CRC outcomes, it is of clinical interest to clarify whether preoperative anaemia has a significant and consistent association with cancer recurrence, host systemic inflammatory and nutritional status, and whether the impact of anaemia could be improved by perioperative blood transfusion.
We hypothesized that patients with CRC and anaemia preoperatively, especially those with one of the anaemic subtypes, might have poorer outcomes due to a poor systemic inflammatory and nutritional status, and that this might be improved by perioperative blood transfusion. To test this hypothesis, we used a database of 592 CRC patients and assessed the importance of preoperative anaemia in CRC treatment.
Method Patients and study design
The study subjects were 592 consecutive CRC patients who underwent elective resection at Kumamoto University hospital in Japan from March 2005 to August 2014. Patients were followed up in our hospital or affiliated hospitals until death or 31 August 2016, whichever came first. The mean follow-up time was 45.1 months (range 2-120 months). Surgical procedures were based on Japanese CRC treatment guidelines [14] [15] [16] . TNM staging was based on the seventh edition of the Union for International Cancer Control classification [17] . Use of these clinical data was approved by the human ethics review committee of the Graduate School of Medicine, Kumamoto University (Institutional Review Board number 1047) and conducted in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines.
Clinicopathological factors and preoperative serum data
Serum samples were collected and tested within 2 weeks of surgery without preoperative blood transfusion. Laboratory measurements included Hb (g/dl), MCV (fl), total lymphocyte count (TLC; per mm 3 ), albumin (g/l), and C-reactive protein (CRP; mg/l). Classification and regression tree (CART) analysis for survival was performed to determine the cut-off value of Hb. The value was 11.7 g/dl, and we defined ≤ 11.7 g/dl as anaemic and > 11.7 g/dl as not anaemic. The anaemia was also classified according to erythrocyte MCV levels: microcytic (< 80 fl), normocytic (80-100 fl) and macrocytic (> 100 fl). We also measured major systematic inflammatory and nutritional scores: the prognostic nutritional index (PNI) and the modified Glasgow Prognostic Score (mGPS). The PNI was calculated as the albumin value (g/l) + (0.005 9 TLC): the cut-off value of PNI was 45 based on previous reports [3, 18] , and mGPS was scored as follows: patients with an elevated serum CRP (> 10.0 mg/l) and hypoalbuminaemia (< 35 g/l) were classified as mGPS 2, those with elevated serum CRP (> 10.0 mg/l) and normal albumin (> 35 g/l) were classified as mGPS 1, and those with normal serum CRP (< 10.0 mg/l) were classified mGPS 0 [9] .
Statistical analysis
All statistical analyses were performed with JMP version 10 (SAS Institute Inc., Cary, North Carolina, USA), or R version 3.3.1 (R Development Core Team). All analyses were performed in patients for whom preoperative Hb and MCV statuses were available (n = 592, Stage 0-IV), excluding recurrence analysis (n = 475, Stage 0-III). Categorical variables were analysed using the chisquare test (case number ≥ 5) or Fisher's exact test (case number < 5), and continuous variables were analysed by Student's t-test. Spline plots, adjusted for age, gender, tumour location and TNM stage, showed that hazard ratio (HR) of relapse or death as a continuous function of Hb. CART analysis for survival was performed to determine the Hb cut-off using overall survival (OS) and relapse-free survival (RFS) probability as end-points [19, 20] . OS was defined as the interval from the date of resection to the date of death from any cause. RFS was defined as the interval from the date of resection to the first date of confirmed recurrence or death. The Kaplan-Meier method and log-rank test were used for survival analysis. Multivariate Cox proportional hazards analysis (using a maximum likelihood model) was adjusted for age, gender, tumour location, depth of tumour invasion, lymph node metastasis, distant metastasis, neoadjuvant chemotherapy, PNI and mGPS to calculate HRs and 95% confidence intervals (CIs). Multivariable logistic regression analysis included age, gender, tumour location, depth of tumour invasion, lymph node metastasis, distant metastasis, neoadjuvant chemotherapy, PNI and mGPS to calculate odds ratios (ORs) and 95% CIs for anaemia or microcytic anaemia. P < 0.05 was considered significant in all analyses.
Results
The association between preoperative anaemia and patient outcome Among the 592 CRC patients, there were 349 (59%) men and 243 (41%) women. Their median age was 68 years (range 19-93 years). To test our hypothesis, we first analysed the association between preoperative anaemia and patient outcome. Clinical significance was assessed visually with the spline plot, which showed HRs for death as a continuous function of the Hb value (Fig. 1a) . The Hb value was prognostic for OS with a declining pattern: risks gradually decreased as the Hb increased. As the Hb value was gradually correlated with OS, we selected CART analysis to find the cut-off value for Hb. Our CART analysis showed that 11.7 g/dl was the optimal cut-off value for OS, and we separated the cases into two populations (anaemic or nonanaemic) from the Hb value ( Figure S1A in the online Supporting Information). Next, we separated the anaemic patients into three populations (microcytic, normocytic or macrocytic) with the MCV value based on a previous report. Of all the 592 patients, 256 (43.2%) had anaemia and 336 (56.8%) were not anaemic; their 5-year OS rates were 59.0% and 79.5%, respectively (P < 0.0001; Fig. 1b) . Further, of the 256 patients with anaemia, 69 (27.0%) had microcytic anaemia, 172 (67.2%) had normocytic anaemia and 15 (5.8%) had macrocytic anaemia; their 5-year OS rates were 50.0%, 60.8% and 79.4%, respectively (P = 0.2198; Fig. 1c ). For RFS as well, we clarified that the Hb value was prognostic with a declining pattern (Fig. 1d ) Our CART analysis showed also that 11.7 g/dl was the optimal cut-off value for RFS (Fig. 1b) . Of the 475 patients in the recurrence analysis, 193 (43.2%) had anaemia and 282 (56.8%) were not anaemic; their 5-year RFS rates were 64.1% and 82.7%, respectively (P < 0.0001; Fig. 1e ). Further, of the 193 patients with anaemia, 49 (25.4%) had microcytic anaemia, 131 (67.9%) had normocytic anaemia and 13 (6.7%) had macrocytic anaemia; their 5-year RFS rates were 48.8%, 68.0% and 76.9%, respectively (P = 0.0372; Fig. 1f ). Multivariate Cox proportional hazards regression analysis showed that anaemia was an independent significant prognosticator (HR 2.33, 95% CI 1.58-3.45, P < 0.0001) and a predictor for relapse (HR 2.05, 95% CI 1.31-3.23, P = 0.0015) ( Tables 1 and S1 ). Furthermore, microcytic anaemia was not an independent significant prognosticator but had a trend to a poorer RFS than other causes (HR 1.72, 95% CI 0.97-3.01, P = 0.0648).
The association of preoperative anaemia with clinicopathological factors and preoperative serum data regarding systemic inflammation and nutrition
To investigate the reason why preoperative anaemia influenced patient outcome, we evaluated the associations with clinicopathological factors and preoperative serum data relating to systemic inflammation and nutrition (Tables 2 and 3) . With regard to clinicopathological factors (Table 2) , anaemia was significantly associated with female gender (P = 0.0295), right-sided tumours (P < 0.0001), greater depth of tumour invasion (P < 0.0001), distant metastases (P = 0.0101), TNM stage (P = 0.0004) and the use of neoadjuvant chemotherapy (P = 0.0357). Furthermore, microcytic anaemia was significantly associated with female gender (P = 0.0014), greater depth of tumour invasion (P = 0.0036), TNM stage (P = 0.0230) and the use of neoadjuvant chemotherapy (P = 0.0421). We next evaluated the association with preoperative serum data relating to systemic inflammation and nutrition (Table 3) . Patients with anaemia had significantly lower TLC (P < 0.0001), lower albumin (P < 0.0001) and higher CRP (P < 0.0001). Additionally, patients with microcytic anaemia had significantly higher CRP (P = 0.0061) than those with other anaemic subtypes. Also, both PNI and mGPS values strongly correlated with preoperative anaemia (PNI, P < 0.0001; mGPS, P < 0.0001), but not with the different subtypes.
Multivariate logistic regression analysis showed that anaemia had an independent strong correlation with rightsided tumours (OR 2.41, 95% CI 1.59-3.68, P < 0.0001), greater depth of tumour invasion (OR 2.62, 95% CI 1.68-4.10, P < 0.0001), use of neoadjuvant chemotherapy (OR Table 4 ).
The association between perioperative blood transfusion and patient outcome
Of 256 patients with anaemia, data for blood transfusion were available for 211. Of these, 78 (40.0%) had perioperative blood transfusions and 133 (60.0%) did not, and their 5-year OS rates were 47.5% and 64.8%, respectively (P = 0.0124; Figure S2A ). Of the 159 patients in the recurrence analysis, 55 (43.2%) had perioperative blood transfusions and 133 (56.8%) did not; their 5-year RFS rates were 45.0% and 72.3%, respectively (P = 0.0010; Figure S2B ). Multivariate Cox proportional hazards regression analysis showed that perioperative blood transfusion had a trend towards poorer OS (HR 1.49, 95% CI 0.96-2.30, P = 0.0753) and was an independent adverse predictor of relapse (HR 1.87, 95% CI 1.06-3.28, P = 0.0317) ( Table 5 ).
Discussion
We tested the hypothesis that preoperative anaemia, especially one of the anaemic subtypes, might correlate with poor patient outcomes, which may be due to poor systemic inflammatory and nutritional status, and that outcome might be improved by perioperative blood transfusion. Using a database of 592 CRC patients, our study showed that preoperative anaemia, especially microcytic anaemia, correlated with poor OS and high recurrent rates. Anaemia was strongly correlated with right-sided tumours, greater depth of tumour invasion, use of neoadjuvant chemotherapy, poorer PNI and higher mGPS values. In particular, microcytic anaemia was strongly correlated with greater depth of tumour invasion and poorer mGPS values (higher CRP), unlike other anaemic subtypes. Contrary to our hypothesis, perioperative blood transfusion for CRC patients with anaemia was associated with adverse patient outcomes. Recent studies have shown a strong association between preoperative anaemia and clinicopathological factors such as female gender, right-sided tumours, greater depth of tumour invasion and distant metastases [9, 10, 21] , which means that preoperative anaemia is associated with features of aggressive tumour biology. Large or high-grade tumours may bleed more easily and cause anaemia, especially microcytic anaemia due to iron deficiency; metastatic tumours are likely to cause abnormal catabolism and malnutrition, causing chronic anaemia [22] ; and patients with right-sided tumours, which tend to have stronger tumour aggressiveness than left-sided tumours, are more likely to have microcytic anaemia due to mechanical tumour bleeding [9, 21] . Our current study not only showed the same results as previous reports, but also added that unlike normocytic anaemia, microcytic anaemia had significantly higher OR for greater depth of tumour invasion, which was not observed in right-sided tumours. This suggests that right-sided tumour-related anaemia cannot be explained solely by mechanical tumour bleeding. Our findings from spline plots have demonstrated that even mild anaemia is associated with a worse prognosis. Considering the differences in immunological mechanisms according to tumour location, anaemia may be correlated with these factors.
Our findings also showed that anaemia strongly correlated with lower TLC, lower albumin and higher CRP. Hypoxia is one of the key characteristics of the tumour microenvironment (TME), which is caused by an insufficient blood supply to support proliferating cancer cells. Accumulated evidence has indicated that anaemia induces hypoxia in the TME, leading not only to upregulation of HIF-1a but also to T-cell apoptosis [3, 23] . This mechanism may induce lower TLC. (8) 27 (11) 21 (6) 27 (11) 10 (15) 17 (10) 0 (0) 2 60 (10) 47 (18) 13 (4) 47 (18) 18 (26) 27 (16) 2 (13) CRP, C-reactive protein; MCV, mean corpuscular volume; mGPS, modified Glasgow Prognostic Score; PNI, prognostic nutritional index; SD, standard deviation; TLC, total lymphocyte count. Unknown serum data were not included in this analysis. *P-value was based on Student's t-test for continuous factors and on the chi-square test (case number ≥ 5) or Fisher's exact test (case number < 5) for categorical factors.
Furthermore, HIF-1a promotes immune suppressive activity through activation of tumour-associated macrophages (TAM) and inhibits effector functions of tumour-infiltrating lymphocytes. These environmental factors could induce tumour revascularization and proliferation [23] . Previous reports have also shown that preoperative anaemia is significantly correlated with preoperative nutritional status, such as body mass index [24] or albumin [9] . Poor nutritional status could lead to iron, folate and vitamin B 12 deficiencies, all of which cause anaemia, and can lead to a poor immune status. It is plausible that preoperative anaemia is more frequent in patients with lower serum albumin. Furthermore, cancer generates cytokines that cause systemic inflammation, which decreases the production and shortens the survival of red blood cells [25] . Therefore, CRP, a systemic inflammation marker, could have a strong association with anaemia. Since these serum marker combinations may explain why anaemia is associated with poor patient outcomes, we evaluated the association between anaemia and PNI (calculated from serum total lymphocyte count and albumin) and mGPS (scored from serum albumin and CRP), which reportedly predict cancer patient outcomes. A few studies have reported that anaemia is more common in CRC patients with increased mGPS [9, 26, 27] . However, to our knowledge, this is the first report of PNI as an anaemiarelated prognostic marker for CRC. Given this evidence, it can be concluded that anaemia is a prognosticator and a predictor for recurrence in CRC patients. Anaemia-induced hypoxic TME might play a key role in tumour proliferation and tumour metastasis [28] and also in the development of resistance to radio-and chemotherapy [29, 30] . Our current study also showed that patients with microcytic anaemia had higher systemic inflammation and poorer clinical outcomes. V€ ayrynen et al. [9] , on the other hand, showed that patients with an elevated inflammatory response tended to have normocytic anaemia. This difference may be due to differences in the number of cases, the analysis (only univariate analysis was performed in V€ ayrynen's paper) and the racial diversity [31] . Given the fact that inflammation is associated with functional iron deficiency leading to microcytosis in the presence of normal whole-body iron stores, further validation studies are needed using data on whole-body iron stores and perioperative iron therapy. Furthermore, anaemia-induced preoperative immunodeficiency might play a key role in promoting the activity of residual cancer cells after surgery, leading to tumour recurrence. V€ ayrynen et al. [9] also showed that BRAF mutation and high microsatellite instability status, key right-sided CRC features, had no significant association with anaemia. However, the fact that anaemia is strongly associated with right-sided CRC highlights the utility of an immunological viewpoint when considering CRC patients with anaemia.
As anaemia plays an independent role in CRC outcome, peri-treatment optimization of Hb levels could lead to improved clinical outcomes. However, our multivariate analysis showed that perioperative blood transfusion was an independent factor for increased mortality and recurrence rate. Although blood transfusion is helpful for anaemic patients, emerging evidence has clarified that it is associated with poor clinical outcomes [32, 33] . In CRC patients who underwent curative resections, perioperative blood transfusions showed detrimental effects on recurrence [34] . However, the mechanism by which perioperative blood transfusion affects on prognosis is unclear. Preclinical mouse models showed that blood transfusions had an adverse effect on NK-cell and T-cell functioning, which enhanced tumour growth and reduced survival [35, 36] . Transfusionrelated immunomodulation or pro-inflammatory changes may contribute to activated tumour status [37] . Therefore, anaemic patients could potentially benefit from anti-inflammatory agents such as aspirin or COX inhibitors [38, 39] , but not from perioperative blood transfusions. With the aim of improving the status of CRC patients with anaemia, modification of the systemic inflammatory response and the patient's nutritional status, and not transfusing just to normalize the Hb value, might have better therapeutic effects.
This study has some limitations. First, our retrospective design in a single institution could cause selection bias. Postoperative treatment heterogeneity was inevitable due to the retrospective design. Second, there are no data about perioperative iron therapy and postoperative treatment. Third, we have no additional serum or tumour molecular parameters for further characterization of anaemia, and no validated data using other independent cohorts. Fourth, previous reports separate the thresholds of anaemia based on gender, but our study set the threshold from a prognostic point of view, using CART analysis for survival. Fifth, the relationship between perioperative blood transfusion and worse outcomes in our study is still unclear, as this could be a surrogate for other factors (such as more challenging surgery as a result of more advanced tumours) which we were unable to determine from our dataset. Sixth, for the RFS analysis in anaemic patients (64 events), there may be a statistical error because the multivariate analysis includes 14 variables. Nonetheless, our results convincingly support the previous findings with a large database of 592 CRC patients. Further validation studies are warranted.
In conclusion, we have found that anaemia, especially microcytic anaemia, is associated with poor patient outcomes, most likely due to poor systemic inflammatory and nutritional status, and that it could not be improved by blood transfusions. Our data suggest that preoperative anaemia and the specific anaemic subtype may serve as a good prognosticator and predictor of recurrence.
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